Time-to-event analysis with treatment arm selection at interim

Statistics in Medicine

Volumn 30, Issue 26, 2011, Pages 3067-3081

  di Scala, L ^a   Glimm, E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adaptive design; Bayesian statistics; Oncology; Treatment selection

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); LOG RANK TEST; MATHEMATICAL ANALYSIS; MEDICAL DECISION MAKING; STATISTICAL SIGNIFICANCE; STUDY DESIGN; TREATMENT PLANNING;

BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DECISION MAKING; HUMANS; LUNG NEOPLASMS; MODELS, STATISTICAL; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80055085677     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4342     Document Type: Article

References (25)

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009; 45:228-247.
2. FDA. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. FDA Doc. Ref. UCM071590, available at.
3. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Disease control rate at 8weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. Journal of Clinical Oncology 2008; 26:463-467.
4. Genz A, Bretz F. Computation of multivariate normal and t probabilities, Springer: Heidelberg, 2009.
5. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
6. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials, Chapman & Hall: London, 2000.
7. Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 2009; 28: 1445-1463.
8. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis, 2nd edition, Chapman & Hall: Boca Raton, 2004.
9. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation, Wiley: New York, 2004.
10. Bernardo JM, Smith AFM. Bayesian Theory. Wiley: Chichester, 1994.
11. Bauer P, Posch M. Letter to be editor: modification of the sample size and the schedule of interim analyses in survival trials based on data inspections. Statistics in Medicine 2004; 23:1333-1335.
12. König F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Statistics in Medicine 2008; 27:1612-1625.
13. Sampson AR, Sill M. Drop-the-losers design: normal case. Biometrical Journal 2005; 47:257-268.
14. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22:689-703.
15. Stallard N, Friede T. Flexible group-sequential designs for clinical trials with treatment selection. Statistics in Medicine 2008; 27:6209-6227.
16. Mardia KV, Kent JT, Bibby MJ. Multivariate Analysis. Academic Press: London, 1979.
17. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55:1286-1290.
18. Posch P, Bauer P. Adaptive two-stage design and the conditional error function. Biometrical Journal 1999; 41:689-696.
19. Iliopoulos I. Estimation of parametric functions in Downton's bivariate exponential distribution. Journal of Statistical Planning and Inference 2003; 117:169-184.
20. Barnes P, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology & Therapeutics 2010; 23:165-171.
21. Cytel Inc. East 5.0 Manual, 2007.
22. Jahn-Eimermacher K, Ingel A. Adaptive trial design: a general methodology for censored time to event data. Contemporary Clinical Trials 2009; 30:171-177.
23. Li G, Shih WJ, Wang Y. Two-stage adaptive design for clinical trials with survival data. Journal of Biopharmaceutical Statistics 2005; 15: 701-718.
24. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer: New York, 2000.
25. FDA. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (Draft). FDA Doc. Ref. UCM201790, available at [February 2010].